Trenchant Announces Amendment to the Option Agreement and Closing of the First Tranche of Its Initial Investment in GNQ Insilico Inc.
Trenchant Announces Amendment to the Option Agreement and Closing of the First Tranche of Its Initial Investment in GNQ Insilico Inc.
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2024) - Trenchant Capital Corp. (CSE: TCC) (the "Company") is pleased to announce that it has entered into an amendment agreement (the "Amendment Agreement") to the previously announced option agreement between the Company and GNQ Insilico Inc. ("GNQ") dated November 30, 2023 (the "Original Option Agreement", and, together with the Amendment Agreement, the "Option Agreement"), pursuant to which the Company has closed the first tranche of its initial investment in GNQ (as defined below), such that the Company now holds approximately 5.6% of the total issued and outstanding common shares in the capital of GNQ (the "GNQ Shares").
不列顛哥倫比亞省溫哥華--(Newsfile Corp.,2024 年 1 月 4 日)——Trenchant Capital Corp.(CSE:TCC)(”公司“)很高興地宣佈,它已經簽訂了修正協議(”修正協議“)轉到公司與GNQ Insilico Inc. 之間先前宣佈的期權協議(”GNQ“) 日期爲 2023 年 11 月 30 日(”原創 期權協議“,以及,連同修正協議,”期權協議“),根據該協議,公司已經完成了對GNQ的第一筆初始投資(定義見下文),因此公司現在持有GNQ資本中已發行和流通普通股總額的約5.6%(”GNQ 股票“)。
As announced by the Company in its news release disseminated on December 1, 2023, the Company entered into the Original Option Agreement with GNQ, pursuant to which GNQ granted the Company the right and option (the "Option") to purchase up to 50% of the GNQ Shares during the period (the "Option Period") commencing on November 30, 2023 and ending on the earlier of November 30, 2026 or the date of a specified liquidity event involving GNQ (as set out in the Option Agreement). Pursuant to the Original Option Agreement, the Company agreed to acquire an initial 20% of the post-investment fully-diluted GNQ Shares for consideration consisting of $2,500,000 and the issuance of 7,500,000 common shares in the capital of the Company (the "Trenchant Shares") to GNQ (collectively, the "Initial Investment").
正如公司在2023年12月1日發佈的新聞稿中宣佈的那樣,公司與GNQ簽訂了原始期權協議,根據該協議,GNQ授予了公司權利和期權(”選項“)在此期間購買高達50%的GNQ股份(”期權期“)從2023年11月30日開始,到2026年11月30日或涉及GNQ的特定流動性事件發生之日(如期權協議所規定)以較早者爲準。根據最初的期權協議,公司同意收購投資後全面攤薄後的GNQ股票的初始20%,包括250萬美元和發行公司資本中的750萬股普通股(”Trenchant 股票“) 到 GNQ(統稱爲”初始投資“)。
Pursuant to the Amendment Agreement, the timeline for the payment of the consideration comprising the Initial Investment has been amended such that it will be satisfied by way of: (a) the payment in cash by Trenchant to GNQ of $700,000 on December 29, 2023; and (b) the payment in cash by Trenchant to GNQ of $1,800,000 and the issuance by Trenchant to GNQ of 7,500,000 Trenchant Shares on or prior to February 29, 2024.
根據修正協議,對構成初始投資的對價的支付時間表進行了修改,將通過以下方式予以滿足:(a)Trenchant於2023年12月29日以現金向GNQ支付70萬美元;(b)Trenchant以現金向GNQ支付1800,000美元,以及Trenchant在當天或之前向GNQ發行750萬股Trenchant股票 2024 年 2 月 29 日。
Concurrently with the execution of the Amendment Agreement and closing of the first tranche of the Initial Investment, the Company, GNQ, and MNH (as defined herein) entered into a unanimous shareholders' agreement (the "Shareholders' Agreement") to establish, among other things, the rights and obligations arising out of or in connection with the ownership of GNQ Shares and to govern the relationship between the holders thereof. Pursuant to the Shareholders' Agreement, the Company has the right to appoint one (1) director to the GNQ board of directors which will increase to two (2) should the Company exercise the Option to acquire a 50% ownership interest in GNQ.
在執行修訂協議和完成第一筆初始投資的同時,公司、GNQ和MNH(定義見此處)簽訂了一致的股東協議(”股東協議“)除其他外,確立因GNQ股票所有權而產生或與之相關的權利和義務,並管理其持有人之間的關係。根據股東協議,公司有權爲GNQ董事會任命一(1)名董事,如果公司行使收購GNQ50%所有權的期權,該董事會將增加到兩(2)名。
GNQ
GNQ
GNQ was formed in August 2023 by My Next Health Inc. ("MNH"), a Delaware incorporated healthcare company with a vision to improve the global healthcare sector by deploying a genomics-based AI and quantum platform for clinical trials and point of care solutions. MNH's platform uses proprietary insights on how systems of genes interact with each other as well as with epigenetic factors to drive key metabolic pathways. These insights are based on more than 15,000 case studies conducted over a decade and are now being scaled and commercialized through a platform that will leverage key exponential technologies to revolutionize personalized healthcare. MNH has exclusive and perpetual global rights to the use of certain technology that relates to functional genomics as well as the supporting clinical data, programs, methods, and interpretation know-how and analytics for use in a number of commercial applications. On November 6th, 2023 GNQ signed a Memorandum of Understanding with a Fortune 100 company towards the development of the in silico clinical trials platform. Both parties are currently working towards the execution of a definitive agreement in respect to the proposed business relationship.
GNQ 由 My Next Health Inc. 於 2023 年 8 月成立。(”MNH“),一家在特拉華州註冊成立的醫療保健公司,其願景是通過部署基於基因組學的人工智能和量子平台進行臨床試驗和護理點解決方案,改善全球醫療保健行業。MNH的平台使用有關基因系統如何相互作用以及與表觀遺傳因子相互作用的專有見解來推動關鍵代謝途徑。這些見解基於十年來進行的15,000多個案例研究,目前正在通過一個平台進行擴展和商業化,該平台將利用關鍵指數技術徹底改變個性化醫療保健。MNH擁有使用與功能基因組學相關的某些技術以及用於多種商業應用的支持性臨床數據、項目、方法、解釋知識和分析的獨家和永久的全球權利。在 11 月 6 日第四,2023 年 GNQ 與一家財富 100 強公司簽署了諒解備忘錄,以開發計算機臨床試驗平台。雙方目前正在努力執行有關擬議業務關係的最終協議。
ON BEHALF OF THE BOARD
代表董事會
TRENCHANT CAPITAL CORP.
TRENCHANT CAPITAL CORP
Per: "Eric Boehnke"
Per: “Eric Boehnke”
Eric Boehnke, CEO
首席執行官埃裏克·博恩克
For further information, please contact:
欲了解更多信息,請聯繫:
Trenchant Capital Corp.
Eric Boehnke, CEO
Phone: (604) 307-4274
Trenchant 資本公司
首席執行官埃裏克·博恩克
電話:(604) 307-4274
TRENCHANT CAPITAL CORP.
TRENCHANT CAPITAL CORP
Certain statements in this press release are forward-looking statements, which reflect the expectations of management regarding the Company's completion of the Initial Investment and related transactions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, statements regarding MNH's and GNQ's business and potential in the industries in which they operate, the Company completing the transactions as described herein or at all, and the obligations to be satisfied under the Option Agreement and Shareholders' Agreement. Such statements are subject to risks and uncertainties that may cause actual results, performance, or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. The risks include that the business of MNH and GNQ may not be feasible or continue as planned, as well as other risks that are customary to transactions of this nature. Further, inflationary pressures, rising interest rates, the global financial climate and the ongoing conflicts in Ukraine and the Middle East and surrounding regions are some additional factors that are affecting current economic conditions and increasing economic uncertainty, which may impact the operating performance, financial position, and future prospects of the Company, MNH, GNQ, and the transaction as a whole. Collectively, the potential impacts of this economic environment pose risks that are currently indescribable and immeasurable. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
本新聞稿中的某些陳述是前瞻性陳述,反映了管理層對公司完成初始投資和相關交易的預期。前瞻性陳述由不純歷史的陳述組成,包括任何有關未來信念、計劃、預期或意圖的陳述,包括但不限於有關MNH和GNQ在其經營行業中的業務和潛力、公司按本文所述完成交易或完全按照期權協議和股東協議應履行的義務的陳述。此類陳述存在風險和不確定性,可能導致實際業績、業績或發展與聲明中包含的結果存在重大差異,包括與公司無法控制的因素相關的風險。風險包括MNH和GNQ的業務可能不可行或無法按計劃繼續,以及此類性質交易所慣用的其他風險。此外,通貨膨脹壓力、利率上升、全球金融環境以及烏克蘭和中東及周邊地區持續的衝突是影響當前經濟狀況和增加經濟不確定性的其他因素,可能會影響公司、MNH、GNQ和整個交易的經營業績、財務狀況和未來前景。總體而言,這種經濟環境的潛在影響構成了目前難以描述和無法估量的風險。無法保證前瞻性陳述所預期的任何事件都會發生,也無法保證如果發生的話,公司將從中獲得什麼好處。除非法律要求,否則公司不打算或義務更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所和市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問
譯文內容由第三人軟體翻譯。